MAPK8, mitogen-activated protein kinase 8, 5599

N. diseases: 520; N. variants: 4
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme 		0.400 GeneticVariation disease UNIPROT
CUI: C0279702
Disease: Conventional (Clear Cell) Renal Cell Carcinoma
Conventional (Clear Cell) Renal Cell Carcinoma 		0.370 GeneticVariation disease UNIPROT
CUI: C0023418
Disease: leukemia
leukemia 		0.090 Biomarker disease BEFREE These findings implicate the JNK pathway in transformation by a human leukemia oncogene. 8524841 1995
CUI: C1332977
Disease: Childhood Leukemia
Childhood Leukemia 		0.080 Biomarker disease BEFREE These findings implicate the JNK pathway in transformation by a human leukemia oncogene. 8524841 1995
CUI: C0149925
Disease: Small cell carcinoma of lung
Small cell carcinoma of lung 		0.030 Biomarker disease BEFREE The findings suggest that UV-stimulated JNK1 activation promotes UV-induced SCLC apoptosis, while a JNK isoform that is variably activated among the SCLC lines may signal a UV-protective response. 9092556 1997
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.100 Biomarker disease BEFREE Hypoglycemia-induced c-Jun phosphorylation is mediated by c-Jun N-terminal kinase 1 and Lyn kinase in drug-resistant human breast carcinoma MCF-7/ADR cells. 9115218 1997
CUI: C0020615
Disease: Hypoglycemia
Hypoglycemia 		0.020 PosttranslationalModification disease BEFREE Hypoglycemia-induced c-Jun phosphorylation is mediated by c-Jun N-terminal kinase 1 and Lyn kinase in drug-resistant human breast carcinoma MCF-7/ADR cells. 9115218 1997
CUI: C0002736
Disease: Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis 		0.020 AlteredExpression disease BEFREE We show that (a) the JNK/SAPK-c-Jun pathway is dramatically overexpressed in ALS spinal cord; (b) the strongest activation occurs in astrocytes, while motor neurons show unusually low expression of the pathway; (c) increased JNK/SAPK expression in glial cells is accompanied by NF-kappa B activation, indicating the presence of a protective response to oxidant sress, which is deficient in motor neurons; (d) activation of JNK/SAPK, c-Jun and NF-kappa B is unrelated to apoptotic cell death. 9413280 1997
CUI: C0036220
Disease: Kaposi Sarcoma
Kaposi Sarcoma 		0.010 AlteredExpression disease BEFREE Moreover, bFGF production by KS and HUVEC is dependent on the activation of the ERK and JNK cascades, which result in the transcriptional activation of the bFGF promoter. 9456251 1998
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.100 AlteredExpression disease BEFREE Expression of JNK-1, ERK-1, p38/RK and MKP-1 proteins was investigated by immunohistochemistry and expression of MKP-1 mRNA by in situ hybridisation in 50 cases of high-grade prostatic intraepithelial neoplasia (PIN), thought to represent the precursor of prostate cancer. 9645439 1998
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.100 AlteredExpression disease BEFREE Expression of JNK-1, ERK-1, p38/RK and MKP-1 proteins was investigated by immunohistochemistry and expression of MKP-1 mRNA by in situ hybridisation in 50 cases of high-grade prostatic intraepithelial neoplasia (PIN), thought to represent the precursor of prostate cancer. 9645439 1998
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.100 AlteredExpression disease BEFREE We have previously found that epidermal growth factor (EGF) mediates growth through the Jun N-terminal kinase/stress-activated kinase (JNK/SAPK) pathway in A549 human lung carcinoma cells. 10022881 1999
CUI: C0016057
Disease: Fibrosarcoma
Fibrosarcoma 		0.020 AlteredExpression disease BEFREE Differential contribution of the ERK and JNK mitogen-activated protein kinase cascades to Ras transformation of HT1080 fibrosarcoma and DLD-1 colon carcinoma cells. 10086335 1999
CUI: C0278595
Disease: Adult Fibrosarcoma
Adult Fibrosarcoma 		0.020 AlteredExpression disease BEFREE Differential contribution of the ERK and JNK mitogen-activated protein kinase cascades to Ras transformation of HT1080 fibrosarcoma and DLD-1 colon carcinoma cells. 10086335 1999
CUI: C4721610
Disease: Carcinoma, Ovarian Epithelial
Carcinoma, Ovarian Epithelial 		0.040 Biomarker disease BEFREE We investigated the response of the mitogen-activated protein kinases, extracellular signal-regulated kinases 1 and 2 (ERK1/2), c-Jun-N-terminal kinase 1 (JNK1), and p38, to cisplatin treatment in the ovarian carcinoma cell line SK-OV-3. 10353733 1999
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary 		0.020 Biomarker disease BEFREE We investigated the response of the mitogen-activated protein kinases, extracellular signal-regulated kinases 1 and 2 (ERK1/2), c-Jun-N-terminal kinase 1 (JNK1), and p38, to cisplatin treatment in the ovarian carcinoma cell line SK-OV-3. 10353733 1999
CUI: C0029925
Disease: Ovarian Carcinoma
Ovarian Carcinoma 		0.010 Biomarker disease BEFREE We investigated the response of the mitogen-activated protein kinases, extracellular signal-regulated kinases 1 and 2 (ERK1/2), c-Jun-N-terminal kinase 1 (JNK1), and p38, to cisplatin treatment in the ovarian carcinoma cell line SK-OV-3. 10353733 1999
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.100 AlteredExpression disease BEFREE Treatment of human hepatoma (HepG2) and murine hepatoma (Hepa1c1c7) cells with tert-butylhydroquinone (tBHQ) or sulforaphane (SUL), two potent phase II enzyme inducers, stimulated the activity of extracellular signal-regulated protein kinase 2 (ERK2) but not c-Jun N-terminal kinase 1. tBHQ and SUL also activated MAPK kinase. 10488090 1999
CUI: C0023903
Disease: Liver neoplasms
Liver neoplasms 		0.030 AlteredExpression group BEFREE Treatment of human hepatoma (HepG2) and murine hepatoma (Hepa1c1c7) cells with tert-butylhydroquinone (tBHQ) or sulforaphane (SUL), two potent phase II enzyme inducers, stimulated the activity of extracellular signal-regulated protein kinase 2 (ERK2) but not c-Jun N-terminal kinase 1. tBHQ and SUL also activated MAPK kinase. 10488090 1999
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis 		0.030 AlteredExpression disease BEFREE In active MS lesions, double-label immunohistochemistry with oligodendrocyte markers showed up-regulation of the nuclear staining for both NF-kappaB and JNK on a large proportion of oligodendrocytes located at the edge of active lesions and on microglia/macrophages throughout plaques. 10550297 1999
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.100 Biomarker disease BEFREE Dominant-negative Jun N-terminal protein kinase (JNK-1) inhibits metabolic oxidative stress during glucose deprivation in a human breast carcinoma cell line. 10719239 2000
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy 		0.050 AlteredExpression disease BEFREE Gene 33/Mig-6, a transcriptionally inducible adapter protein that binds GTP-Cdc42 and activates SAPK/JNK. A potential marker transcript for chronic pathologic conditions, such as diabetic nephropathy. Possible role in the response to persistent stress. 10749885 2000
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma 		0.100 Biomarker disease BEFREE Our findings demonstrate that the constitutive activation of ERK1/2, JNK1 and p38 is not a feature of colorectal cancers. 10769637 2000
CUI: C0038454
Disease: Cerebrovascular accident
Cerebrovascular accident 		0.210 Biomarker group RGD Inhibition of JNK-1 activation might become an innovative means of therapy for stroke treatment in the future. 10773432 2000
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme 		0.400 Biomarker disease BEFREE Here, the influence of JNK on basal (unstimulated) growth of human tumor glioblastoma T98G cells was investigated using highly specific JNK antisense oligonucleotides to inhibit JNK expression. 10825181 2000